Cross-modal associations in synaesthesia: vowel colours in the ear of the beholder

Human speech conveys many forms of information, but for some exceptional individuals (synaesthetes), listening to speech sounds can automatically induce visual percepts such as colours. In this experiment, grapheme–colour synaesthetes and controls were asked to assign colours, or shades of grey, to different vowel sounds. We then investigated whether the acoustic content of these vowel sounds influenced participants’ colour and grey-shade choices. We found that both colour and grey-shade associations varied systematically with vowel changes. The colour effect was significant for both participant groups, but significantly stronger and more consistent for synaesthetes. Because not all vowel sounds that we used are “translatable” into graphemes, we conclude that acoustic–phonetic influences co-exist with established graphemic influences in the cross-modal correspondences of both synaesthetes and non-synaesthetes

Characteristics of Ten Tropical Hardwoods from Certified Forests in Bolivia Part I Weathering Characteristics and Dimensional Change

Ten tropical hardwoods from Bolivia were evaluated for weathering performance (erosion rate, dimensional stability, warping, surface checking, and splitting). The wood species were Amburana cearensis (roble), Anadenanthera macrocarpa (curupau), Aspidosperma cylindrocarpon (jichituriqui), Astronium urundeuva (cuchi), Caesalpinia cf. pluviosa (momoqui), Diplotropis purpurea (sucupira), Guibourtia chodatiana (sirari), Phyllostylon rhamnoides (cuta), Schinopsis cf. quebracho-colorado (soto), and Tabebuia spp. (lapacho group) (tajibo or ipe). Eucalyptus marginata (jarrah) from Australia and Tectona grandis (teak), both naturally grown from Burma and plantation-grown from Central America, were included in the study for comparison. The dimensional change for the species from Bolivia, commensurate with a change in relative humidity (RH) from 30% to 90%, varied from about 1.6% and 2.0% (radial and tangential directions) for Amburana cearensis to 2.2% and 4.1% (radial and tangential) for Anadenanthera macrocarpa. The dimensional change for teak was 1.3% and 2.5% (radial and tangential) for the same change in relative humidity. None of the Bolivian species was completely free of warp or surface checks; however, Anadenanthera macrocarpa, Aspidosperma cylindrocarpon, and Schinopsis cf. quebracho-colorado performed almost as well as teak. The erosion rate of several of the wood species was considerably slower than that of teak, and there was little correlation between wood density and erosion rate. Part 2 of this report will include information on the decay resistance (natural durability) of these species

IMPACTS OF REDUCED PESTICIDE USE ON THE PROFITABILITY OF THE FRUIT AND VEGETABLE SECTOR

Environmental Economics and Policy,

Characteristics of Ten Tropical Hardwoods from Certified Forests in Bolivia. Part II. Natural Durability to Decay Fungi

The natural durability of 10 lesser known, commercially available Bolivian hardwoods to decay fungi was evaluated using a modified ASTM soil-block analysis for 12 weeks. The blocks were then retested for an additional 12 weeks to determine their level of decay resistance, as determined by percentage of weight loss. Astronium urundeuva, Caesalpinia cf. pluviosa, Schinopsis quebrachocolorado, and Tabebuia sp. (Iapacho group) were found to be highly resistant to decay; Amburana cearensis, Anadenanthera colubrina (syn: A. macrocarpa), Aspidosperma cylindrocarpon, Diplotropis purpurea, and Guibourtia chodatiana, resistant to decay; and Phyllostylon rhamnoides, moderately resistant to decay. We conclude that an extended soil-bottle test is an effective tool for assessing the level of natural durability of these and other tropical species

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

Despite significant research efforts aimed at understanding the neurobiological underpinnings of psychiatric disorders, the diagnosis and the evaluation of treatment of these disorders are still based solely on relatively subjective assessment of symptoms. Therefore, biological markers which could improve the current classification of psychiatry disorders, and in perspective stratify patients on a biological basis into more homogeneous clinically distinct subgroups, are highly needed. In order to identify novel candidate biological markers for major depression and schizophrenia, we have applied a focused proteomic approach using plasma samples from a large case-control collection. Patients were diagnosed according to DSM criteria using structured interviews and a number of additional clinical variables and demographic information were assessed. Plasma samples from 245 depressed patients, 229 schizophrenic patients and 254 controls were submitted to multi analyte profiling allowing the evaluation of up to 79 proteins, including a series of cytokines, chemokines and neurotrophins previously suggested to be involved in the pathophysiology of depression and schizophrenia. Univariate data analysis showed more significant p-values than would be expected by chance and highlighted several proteins belonging to pathways or mechanisms previously suspected to be involved in the pathophysiology of major depression or schizophrenia, such as insulin and MMP-9 for depression, and BDNF, EGF and a number of chemokines for schizophrenia. Multivariate analysis was carried out to improve the differentiation of cases from controls and identify the most informative panel of markers. The results illustrate the potential of plasma biomarker profiling for psychiatric disorders, when conducted in large collections. The study highlighted a set of analytes as candidate biomarker signatures for depression and schizophrenia, warranting further investigation in independent collections

Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.

Funder: Medical Research Council; FundRef: http://dx.doi.org/10.13039/501100000265; Grant(s): MRC Epidemiology Unit programme: MC_UU_12015/4.OBJECTIVE: To review evidence on routinely prescribed drugs in the UK that could upregulate or downregulate ACE2 and potentially affect COVID-19 disease. DESIGN: Systematic review. DATA SOURCE: MEDLINE, EMBASE, CINAHL, the Cochrane Library and Web of Science. STUDY SELECTION: Any design with animal or human models examining a currently prescribed UK drug compared with a control, placebo or sham group, and reporting an effect on ACE2 level, activity or gene expression. DATA EXTRACTION AND SYNTHESIS: MEDLINE, EMBASE, CINAHL, the Cochrane Library, Web of Science and OpenGrey from inception to 1 April 2020. Methodological quality was assessed using the SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) risk-of-bias tool for animal studies and Cochrane risk-of-bias tool for human studies. RESULTS: We screened 3360 titles and included 112 studies with 21 different drug classes identified as influencing ACE2 activity. Ten studies were in humans and one hundred and two were in animal models None examined ACE2 in human lungs. The most frequently examined drugs were angiotensin receptor blockers (ARBs) (n=55) and ACE inhibitors (ACE-I) (n=22). More studies reported upregulation than downregulation with ACE-I (n=22), ARBs (n=55), insulin (n=8), thiazolidinedione (n=7) aldosterone agonists (n=3), statins (n=5), oestrogens (n=5) calcium channel blockers (n=3) glucagon-like peptide 1 (GLP-1) agonists (n=2) and Non-steroidal anti-inflammatory drugs (NSAIDs) (n=2). CONCLUSIONS: There is an abundance of the academic literature and media reports on the potential of drugs that could attenuate or exacerbate COVID-19 disease. This is leading to trials of repurposed drugs and uncertainty among patients and clinicians concerning continuation or cessation of prescribed medications. Our review indicates that the impact of currently prescribed drugs on ACE2 has been poorly studied in vivo, particularly in human lungs where the SARS-CoV-2 virus appears to enact its pathogenic effects. We found no convincing evidence to justify starting or stopping currently prescribed drugs to influence outcomes of COVID-19 disease

Transmission and Transport of Energy in the Western U.S. and Canada: A Law and Policy Road Map

This collection of short essays arose from the inaugural meeting of the Idaho Symposium on Energy in the West, which was held in November, 2014. The topic for this first Symposium was Transmission and Transport of Energy in the Western U.S. and Canada: A Law and Policy Road Map. The essays in this collection provide a notable introduction to the major energy issues facing the West today. Topics include: building a resilient legal architecture for western energy production; natural gas flaring; transmission planning for wind energy; utilities and rooftop solar; special considerations for western states and the Clean Power Plan; the Clean Power Plan\u27s implications for the western grid; siting renewable energy on public lands; and implications of utility reform in New York and Hawaii for the Northwest

Histological Observation of Islet Hemorrhage Induced by Diagnostic Ultrasound with Contrast Agent in Rat Pancreas

Contrast enhanced diagnostic ultrasound CEDUS has been shown to induce capillary hemorrhage in heart and kidney. This study characterized the capillary hemorrhage induced in rat pancreas. The pancreata of anesthetized hairless rats were accessed by laparotomy. A 1.5 MHz diagnostic ultrasound probe with 2.3 MPa peak rarefactional pressure amplitude and 1 s intermittent trigger was used to scan the pancreas, located at the focus (3.8 cm), through saline coupling. The probe was swept to expose the entire organ in 5 min during infusion of Definity® contrast agent at 10 µL/kg/min, and this was repeated in a reverse sweep. The entire pancreas was removed, spread flat for fixation and histological slides were prepared from the mid-plane. Slides were scored blind for islet hemorrhage over the entire area of the organ. Intra-islet microlesions were evident and hemorrhage surrounded many islets. The hemorrhage often impacted nearby acini, and expanded into inter-lobular septa. In CEDUS pancreata removed soon after scanning, 76.2±11.8% (n = 6) of islets had evidence of hemorrhage and/or islet microlesions compared to 1.1±2.5% (n = 5) for sham CEDUS (P<0.001). In pancreata removed after 4 hr, fibrin formation was detected by immunohistology in the hemorrhage and intra-islet microlesions. Diagnostic ultrasound with contrast agent induced substantial capillary hemorrhage in rat pancreas, concentrated particularly in the islets

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice. OBJECTIVE We test the ability of GSK1521498 to reduce alcohol consumption and compare its intrinsic efficacy to that of naltrexone by comparing the two drugs at doses matched for equivalent receptor occupancy. METHODS Thirty-six C57BL/6J mice were tested in a DID procedure. In 2-day cycles, animals experienced one baseline, injection-free session, and one test session when they received two injections, one of test drug and one placebo. All animals received GSK1521498 (0, 0.1, 1 and 3 mg/kg, i.p., 30 min pre-treatment) and naltrexone (0, 0.1, 1 and 3 mg/kg, s.c. 10 min pre-treatment) in a cross-over design. Receptor occupancies following the same doses were determined ex vivo in separate groups by autoradiography, using [3H]DAMGO. Binding in the region of interest was measured integrally by computer-assisted microdensitometry and corrected for non-specific binding. RESULTS Both GSK1521498 and naltrexone dose-dependently decreased ethanol consumption. When drug doses were matched for 70-75 % receptor occupancy, GSK1521498 3 mg/kg, i.p., caused a 2.5-fold greater reduction in alcohol consumption than naltrexone 0.1 mg/kg, s.c. Both GSK1521498 and naltrexone significantly reduced sucrose consumption at a dose of 1 mg/kg but not 0.1 mg/kg. In a test of conditioned taste aversion, GSK1521498 (3 mg/kg) reduced sucrose consumption 24 h following exposure to a conditioning injection. CONCLUSIONS Both opioid receptor antagonists reduced alcohol consumption but GK1521498 has higher intrinsic efficacy than naltrexone